



Atty Dkt 9400-0013  
PXE-013.US  
PATENT

OCT 19 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on October 9, 2001.

10/9/01  
Date

Karen K. Dennis  
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

FRANCIS, et al.

Serial No.: 09/888,049

Group Art Unit: 1619

Filing Date: July 21, 2001

Examiner: Unassigned

Title: COMPOSITIONS AND METHODS FOR USE THEREOF IN  
MODIFYING THE GENOMES OF MICROORGANISMS

TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is an Information Disclosure Statement, including a Form PTO-1449 and copies of the cited references. It is believed that no fee is due.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: 9 Oct 2001

By: Gary R. Fabian  
Gary R. Fabian, Ph.D.  
Registration No. 33,875  
Agent for Applicants

XENOCORPORATION  
860 Atlantic Avenue  
Alameda, CA 94501  
Telephone: 510-291-6135  
Facsimile: 510-291-6134

Atty Dkt 9400-0013  
PXE-013.US  
PATENT

TECH CENTER 1600/2900  
OCT 19 2001

RECEIVED

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on October 9, 2001

10/9/01  
Date

Patricia K. Lewis  
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

FRANCIS, et al.

Serial No.: 09/888,049

Group Art Unit: 1619

Filing Date: July 21, 2001

Examiner: Unassigned

Title: COMPOSITIONS AND METHODS FOR USE THEREOF IN  
MODIFYING THE GENOMES OF MICROORGANISMS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The information listed below may be material to the examination of the above-identified application. Copies of the information not previously cited to the Examiner, and a completed PTO-1449 form, are also submitted herewith. The Examiner is requested to make this information of official record in the application. No additional fee is required. The information includes:

United States Patent No. 5,650,135 issued July 22, 1997 to Contag et al.;  
United States Patent No. 6,020,121 issued February 1, 2000 to Bao et al.;  
United States Patent No. 6,217,847 issued April 17, 2000 to Contag et al.;  
International Publication No. WO 96/40979 A1 published December 19, 1996;  
International Publication No. WO 97/11690 A2, A3 published April 3, 1997;  
International Publication No. WO 97/18841 published May 29, 1997;  
International Publication No. WO 97/40381 A1 published October 30, 1997;



International Publication No. WO 99/14311 A published March 25, 1999;  
International Publication No. WO 00/36106 published June 22, 2000;  
International Publication No. WO 01/18195 A2 published March 15, 2001;  
International Publication No. WO 01/18225 A1 published March 15, 2001;  
International Publication No. WO 01/37195 A2 published May 25, 2001;  
European Publication No. EP 0 639 641 A published February 22, 1995;  
Hahn, T., et al., "Construction and Analysis of Modified Tn4001 Conferring Chloramphenicol Resistance in Mycoplasma *Pneumoniae*," *Plasmid* 41:120-124 (1999);  
Jacobs et al., "Highly Bioluminescent *Bacillus Subtilis* Obtained Through High-level Expression of a *luxAB* Fusion Gene," *Mol. Gen. Genet.* 230:251-256 (1991);  
Phillips-Jones, M.K. "Bioluminescence (*lux*) Expression in the Anaerobe *Clostridium Perfringens*," *FEMS Microbiology Letters* 106:265-270 (1993);  
Loimaranta, et al., "Generation of Bioluminescent *Streptococcus mutans* and Its Usage in Rapid Analysis of the Efficacy of Antimicrobial Compounds" *Antimicrobial Agents and Chemotherapy* 42(8):1906-1910 (1998);  
Meighen, E.A., "Bacterial Bioluminescence: Organization, Regulation, and Application of the *lux* Genes," *BASEB Journal* 7(11):1016-1022 (1993);  
O'Connell, K.P., et al., "Identification of Cold Shock Gene Loci in *Sinorhizobium meliloti* by Using a *luxAB* Reporter Transposon," *Appl. Environ. Microbiol.* 66(1):401-405 (2000);  
Roy, G., et al., "Episomal and Stable Expression of the Luciferase Reporter Gene for Quantifying *Leishmania* spp. Infections in Macrophages and in Animal Models," *Molecular and Biochemical Parasitology* 110:195-206 (2000);  
Sibakov, M., et al., "Secretion of TEM  $\beta$ -Lactamase with Signal Sequences Isolated from the Chromosome of *Lactococcus lactis* subsp. *lactis*," *Appl. Environ. Microbiology* 57(2):341-348 (1991);  
Sohaskey et al., "Construction and Application of Plasmid-and Transposon-Based Promoter-Probe Vectors for *Streptomyces* spp. That Employ a *Vibrio harveyi* Luciferase Reporter Cassette," *Journal of Bacteriology* 174(2):367-376 (1992);



Atty Dkt No. 9400-0013

USSN: 09/888,049

PATENT

TECH CENTER 1600/2600

OCT 19 2001

RECEIVED

Steidler, et al., "The Expression of *Photinus pyralis* Luciferase Gene in *Staphylococcus aureus* Cowan I allows the Development of a Live Amplifiable Tool for Immunodetection" *Applied and Environmental Microbiology* 62(7):2356-2359 (1996);

Steinmann, et al., "Saturation Mutagenesis in *Escherichia coli* of a Cloned *Xanthomonas campestris* DNA Fragment with the *lux* Transposon Tn4431 Using the Delivery Plasmid pDS1, Thermosensitive in Replication," *Appl. Microbiol. Biotechnol.* 40:356-360 (1993);

Ulitzur, S., J. "Established Technologies and New Approaches in Applying Luminous Bacteria for Analytical Purposes," *Biolumin Chemilumin.* 12:179-92 (1997); and

Zhang et al., "Bioluminescence for Biological Sensing in Living Mammals," *Oxygen Transport to Tissue XXI*, edited by Eke and Delpy. Kluwer Academic/Plenum Publishers, New York, (1999).

This Information Disclosure Statement is not to be construed as a representation that: (i) additional information material to the examination of this application does not exist; (ii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iii) the above information constitutes prior art to the subject invention.

Respectfully submitted,

Date:

9 Oct 2001

By:



Gary R. Fabian  
Registration No. 33,875  
Agent for Applicants

XENOCEN CORPORATION  
860 Atlantic Avenue  
Alameda, CA 94501  
Telephone: 510-291-6135  
Facsimile: 510-291-6134